BEIJING, Dec. 7, 2011 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the
"Company"), one of the leading plasma-based biopharmaceutical
companies in the People's Republic of
China, today announced it will be presenting at the
Oppenheimer & Co. 22nd Annual Healthcare Conference taking
place December 13-14, 2011 at the
Waldorf-Astoria Hotel in New York
City.
Mr. Tristan Kuo, Chief Financial
Officer of China Biologics, will be in attendance. The Company is
scheduled to present on Wednesday, December
14, 2011 from 3:55 PM to 4:25
PM, and will also be taking several 1-on-1 meetings with
investors.
For more information, please contact your Oppenheimer & Co.
institutional sales representative.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd. and Guizhou Taibang Biological Co., and its equity
investment in Xi'an Huitian Blood Products Co., Ltd., is one of the
leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated
biologic products company with plasma collection, production and
manufacturing, research and development, and commercial operations.
The Company's plasma-based biopharmaceutical products are
irreplaceable during medical emergencies and are used for the
prevention and treatment of various diseases. The Company sells its
products to hospitals and other healthcare facilities in
China. Please see the Company's
website at www.chinabiologic.com for additional information.
www.chinabiologic.com
Company contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Telephone: +86 53 8620 2206
Email: IR@chinabiologic.com
SOURCE China Biologic Products, Inc.